Health
Novo Nordisk Obesity Drugs Probed by UK Regulator Over Suicidal Thoughts
- UK started investigation after EU watchdog opened probe
- Reports linked to various diabetes and weight-loss treatments
This article is for subscribers only.
Drugs from Novo Nordisk and Eli Lilly Co. are being investigated by the UK medicines regulator over patient reports of suicidal thoughts, shortly after Europe’s watchdog opened a probe into the same issue.
The UK Medicines & Healthcare products Regulatory Agency has received several reports of suspected adverse drug reactions associated with such behavior possibly related to semaglutide — the active ingredient in Novo’s diabetes and weight-loss drugs Ozempic and Wegovy, the agency said in a statement Wednesday. The MHRA has also received reports linked to liraglutide — the active ingredient in Saxenda.